Your Employer Dropped GLP-1 Coverage: What to Do Now

Open enrollment packets are landing, and for a growing number of people the news is bad: their employer is dropping GLP-1 coverage for weight management in 2027. Business Group on Health's latest survey found that 14% of surveyed employers have already dropped or plan to drop that coverage by 2027, up from 10% earlier this year (Insurance Business, September 2026). If you're one of them, you have a few months to plan. This guide is the playbook: how to confirm the change actually hits you, what to do before the end date, and how to pick a cash-pay option you can sustain.

If your plan still covers GLP-1s and you're fighting a denial instead, start with our appeal guide. If you simply want the full price list, see GLP-1 without insurance.

What's happening with employer GLP-1 coverage

The numbers moved fast this year. In May, a Business Group on Health survey of 105 employers found that 72% of those covering GLP-1s for weight management expected to keep doing so in 2027, while 10% said they likely would not (SHRM, May 2026). By September, the group's follow-up survey of 127 employers showed the share of employers covering GLP-1s for weight management falling from 72% in 2025 to 60% in 2026 (Insurance Business, September 2026).

Big names are part of it. Starbucks confirmed it will stop covering GLP-1s prescribed for weight loss starting in October 2026, while coverage may remain for other medical conditions (SHRM, August 2026).

The effect shows up in real usage data. In Massachusetts, where several major insurers ended routine weight-loss coverage, 112,000 fewer commercially insured members used a GLP-1 for weight loss between 2025 and the first quarter of 2026, a 52% decline, according to data presented to the state's Health Policy Commission (GBH, September 17, 2026).

The reason is money, not doubts about the drugs. Pharmacy now accounts for about 25% of surveyed employers' total health spending (Insurance Business).

Step 1: Confirm the change actually applies to you

Rumors spread faster than plan documents. Before you change anything, get the facts in writing.

Read your 2027 Summary of Benefits and Coverage (SBC). Every plan must give you this plain-language summary at key points like enrollment and renewal (HealthCare.gov). Look under "Excluded services" and the prescription drug section for language like "weight loss drugs" or "anti-obesity medications."

Check the 2027 formulary. Search your pharmacy benefit manager's formulary for your exact drug (Wegovy, Zepbound, Saxenda). Note whether it's removed entirely or only excluded for weight management.

Email HR or the benefits team. Ask three specific questions, and keep the reply:

1. What is the exact date the exclusion takes effect?
2. Does it apply to weight management only, or to all GLP-1 indications?
3. Is there any transition period or continuity-of-care exception for current users?

Weight management vs. diabetes coverage

Many employers cutting GLP-1s, Starbucks among them, are removing the weight-management indication while keeping coverage when the drugs are prescribed for conditions like diabetes (Insurance Business). If you have a documented type 2 diabetes diagnosis, your diabetes medication may be unaffected. That coverage depends on your actual medical history. Don't ask a prescriber to change a diagnosis or code to keep coverage: it's insurance fraud, and a reputable clinician will refuse.

Some plans also cover GLP-1s for other FDA-labeled uses (Wegovy, for example, is also approved to reduce the risk of major cardiovascular events in certain adults with established heart disease; see the Wegovy prescribing information). Ask HR whether those are carved out, and let your prescriber decide whether any of them legitimately apply to you.

Step 2: Use the time before your coverage ends

You likely have until January 1, 2027, though some plans (like Starbucks') change mid-year. Here's how to use that window.

Refill on schedule, within plan rules. Fill every covered prescription as soon as your plan allows. Don't try to stockpile beyond your plan's refill limits. Pharmacies and plans track early refills, and you'll just get rejected.

Ask about a transition fill. Some plans and pharmacy benefit managers grant short transition supplies for members already on a drug that's being removed. There's no universal rule for this, so ask HR and the plan directly.

Compare your spouse's or partner's plan. Open enrollment is your one chance a year to switch plans. If a household member has access to a plan that still covers weight-management GLP-1s, compare the full cost: premiums, deductible, and whether prior authorization will be required. Our prior authorization guide covers what approvals typically require.

Set aside HSA or FSA money. IRS Publication 502 counts prescribed drugs as medical expenses, and it includes weight-loss costs when the weight loss treats a specific disease diagnosed by a physician, such as obesity or hypertension (IRS Publication 502). If you'll be paying cash in 2027, consider raising your FSA election during open enrollment. Ask your prescriber for a letter of medical necessity in case your plan administrator asks for documentation.

Know when an appeal makes sense. A flat plan exclusion is hard to overturn, because the drug is excluded by design rather than denied for you specifically. Appeals work better when the denial is about missing clinical documentation. Our appeal playbook and medical necessity letter guide cover when it's worth the effort.

Don't plan a gap. Many people assume they'll just pause treatment. The evidence suggests that's costly. In the STEP 4 trial, adults who continued semaglutide after a 20-week run-in kept losing weight, while those switched to placebo regained weight (JAMA, 2021). The Wegovy injection label also says that after 2 or more consecutive missed weekly doses, dose escalation should restart at a lower dose to reduce the risk of GI side effects (Wegovy prescribing information, DailyMed). More on that in our guide to stopping GLP-1s and weight regain.

Step 3: Pick a cash-pay option

Once coverage ends, you have three realistic paths. All require a prescription from a licensed provider. Prices below are from our September 2026 pricing verification and may change; check the live pricing tool for current rates.

Path A: Stay on the same brand-name drug through the manufacturer

This is the lowest-disruption option if you're on Wegovy or Zepbound now. You keep the same drug and the same dose.

Program	Medication	Monthly price (Oct 2026)
NovoCare Pharmacy	Wegovy pen	$199 for first 2 fills at 0.25mg/0.5mg (through Dec 31, 2026), then $349 (0.25–2.4mg); $399 for 7.2mg
NovoCare Pharmacy	Wegovy pill	$149 (1.5mg), $199 (4mg), $299 (9mg and 25mg)
LillyDirect	Zepbound	$299 (2.5mg), $399 (5mg), $449 (7.5–15mg with a refill within 45 days; $499 at 7.5mg and $699 at 10–15mg otherwise)
LillyDirect	Foundayo (oral)	$149 (0.8mg); $149 (2.5mg) and $199 (5.5mg) temporarily through Dec 31, 2026, regularly $199 and $299; $299 (9mg); $299 at 14.5–17.2mg with a refill within 45 days

Sources: NovoCare Pharmacy and LillyDirect, per RxPickr's October 2026 pricing check. LillyDirect's self-pay program requires refills within 45 days to keep program pricing, so plan your first cash fill to land right after your last covered one.

If you're on a maintenance dose, the math matters. A Zepbound patient at 10mg would pay $449/month through LillyDirect, or $5,388 a year. That's the number to compare against a spouse's plan premium.

Path B: Switch to an oral option

The Wegovy pill (Novo Nordisk, December 2025) and Foundayo, orforglipron (FDA, April 2026), are both FDA-approved oral options for weight management, and their starting doses are the cheapest brand-name entry points at $149/month. Switching from an injection to a pill is a new treatment, not a continuation, so your prescriber will set the dose. See switching to Foundayo and Foundayo vs. the Wegovy pill.

Path C: Compounded GLP-1s through a telehealth provider

Compounded semaglutide and tirzepatide cost less, often under $200/month. They contain the same active ingredient as the brand-name drugs but are not FDA-approved as finished products, and they haven't been studied in the large randomized trials behind Wegovy and Zepbound. Read is compounded semaglutide safe? before you decide.

Step 4: Switch safely

Changing where your medication comes from can also change what you're taking. Treat any of these as a real medication change:

• Zepbound to Wegovy (or the reverse). Tirzepatide and semaglutide are different drugs, and there's no simple dose conversion between them. See tirzepatide vs. semaglutide.
• Brand to compounded. Compounded vials can come in different concentrations than brand pens, so the number of units you draw may not match what you're used to. Follow your new prescriber's instructions and the pharmacy's label exactly.
• Injection to pill. Oral doses are measured differently, and your prescriber will start you on a titration schedule.

Tell your new provider exactly what you've been taking, at what dose, and when your last dose was. If you've missed doses, say so. GI side effects like nausea may return after a restart or switch, which is why the Wegovy injection label calls for re-titrating after missed doses (Wegovy prescribing information, DailyMed); our side effects guide covers what's typical and when to call a clinician.

Which telehealth providers fit a coverage-loss switch

If you're moving to compounded medication, these providers offer straightforward pricing with no separate insurance workflow to manage.

Prices per each provider's website, verified October 2026 (TrimRx and Oak Longevity carried forward from our September 2026 check); prices may vary. Other options include TrimRx ($199/month flat per its own pricing guides; we could not confirm plan tiers at checkout) and Oak Longevity ($133/month on a 3-month supply with its checkout code, billed upfront, $200/month without; higher doses may cost more). See our full provider comparison for the rest.

The short version

Confirm the exclusion and its date in writing. Refill on schedule while you're covered. Use open enrollment to compare a partner's plan and fund an FSA. Then line up your cash-pay route before your last covered fill, so there's no gap. GLP-1 medications require a prescription, and any switch in drug, dose, or formulation should go through a licensed healthcare provider. The RxPickr quiz can narrow down which option fits your budget.